EP0632893A1 - Immuno-essais par fluorescence au moyen de matrices fluorescentes exemptes d'agregat et de liant de serum - Google Patents
Immuno-essais par fluorescence au moyen de matrices fluorescentes exemptes d'agregat et de liant de serumInfo
- Publication number
- EP0632893A1 EP0632893A1 EP93908390A EP93908390A EP0632893A1 EP 0632893 A1 EP0632893 A1 EP 0632893A1 EP 93908390 A EP93908390 A EP 93908390A EP 93908390 A EP93908390 A EP 93908390A EP 0632893 A1 EP0632893 A1 EP 0632893A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- probe
- receptor
- target analyte
- labeled
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 102
- 238000003018 immunoassay Methods 0.000 title claims abstract description 53
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 47
- 230000027455 binding Effects 0.000 title abstract description 46
- 238000009739 binding Methods 0.000 title abstract description 46
- 230000002776 aggregation Effects 0.000 title abstract description 6
- 238000004220 aggregation Methods 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 191
- 210000004369 blood Anatomy 0.000 claims abstract description 56
- 239000008280 blood Substances 0.000 claims abstract description 56
- 239000013060 biological fluid Substances 0.000 claims abstract description 14
- 210000002700 urine Anatomy 0.000 claims abstract description 9
- 239000000523 sample Substances 0.000 claims description 224
- 229960005156 digoxin Drugs 0.000 claims description 128
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 120
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 120
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 120
- 239000012491 analyte Substances 0.000 claims description 108
- MIMIOXRXVPQFEI-UHFFFAOYSA-N dicarboxysilicon Chemical compound OC(=O)[Si]C(O)=O MIMIOXRXVPQFEI-UHFFFAOYSA-N 0.000 claims description 78
- 230000010287 polarization Effects 0.000 claims description 55
- 238000005259 measurement Methods 0.000 claims description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 239000003446 ligand Substances 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 239000007787 solid Substances 0.000 claims description 42
- 230000001052 transient effect Effects 0.000 claims description 38
- 239000003550 marker Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 229920001223 polyethylene glycol Polymers 0.000 claims description 27
- -1 polyoxy Polymers 0.000 claims description 27
- 125000004429 atom Chemical group 0.000 claims description 22
- 210000002381 plasma Anatomy 0.000 claims description 22
- 230000003381 solubilizing effect Effects 0.000 claims description 19
- 201000005404 rubella Diseases 0.000 claims description 17
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 150000002678 macrocyclic compounds Chemical class 0.000 claims description 12
- 229960002393 primidone Drugs 0.000 claims description 12
- 238000002875 fluorescence polarization Methods 0.000 claims description 11
- 229960002695 phenobarbital Drugs 0.000 claims description 11
- 229960000648 digitoxin Drugs 0.000 claims description 10
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical class N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims description 10
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 10
- 229940034208 thyroxine Drugs 0.000 claims description 10
- 241000710799 Rubella virus Species 0.000 claims description 9
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 9
- 229910052710 silicon Inorganic materials 0.000 claims description 9
- 239000010703 silicon Substances 0.000 claims description 9
- 229960000278 theophylline Drugs 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 8
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 claims description 8
- KEECCEWTUVWFCV-UHFFFAOYSA-N N-acetylprocainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1 KEECCEWTUVWFCV-UHFFFAOYSA-N 0.000 claims description 8
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 claims description 8
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 210000003743 erythrocyte Anatomy 0.000 claims description 6
- 229960002036 phenytoin Drugs 0.000 claims description 6
- 150000004033 porphyrin derivatives Chemical class 0.000 claims description 6
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 239000013068 control sample Substances 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- VXUOFDJKYGDUJI-UHFFFAOYSA-N (2-hydroxy-3-tetradecanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C VXUOFDJKYGDUJI-UHFFFAOYSA-N 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 229910052732 germanium Inorganic materials 0.000 claims description 3
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 229920003169 water-soluble polymer Polymers 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 2
- 230000002456 anti-arthritic effect Effects 0.000 claims description 2
- 230000001088 anti-asthma Effects 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims description 2
- 229940097217 cardiac glycoside Drugs 0.000 claims description 2
- 239000002368 cardiac glycoside Substances 0.000 claims description 2
- 150000004038 corrins Chemical class 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 239000011369 resultant mixture Substances 0.000 claims description 2
- 229930002534 steroid glycoside Natural products 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- HMSMOZAIMDNRBW-UHFFFAOYSA-N 100572-96-1 Chemical class C1=CC2=NC1=CC=C(N1)C=CC1=C(N1)C=CC1=CC=C1C=CC2=N1 HMSMOZAIMDNRBW-UHFFFAOYSA-N 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- COFLCBMDHTVQRA-UHFFFAOYSA-N sapphyrin Chemical class N1C(C=2NC(C=C3N=C(C=C4NC(=C5)C=C4)C=C3)=CC=2)=CC=C1C=C1C=CC5=N1 COFLCBMDHTVQRA-UHFFFAOYSA-N 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 134
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 108
- 238000006243 chemical reaction Methods 0.000 description 63
- 102000005962 receptors Human genes 0.000 description 61
- 108020003175 receptors Proteins 0.000 description 61
- 239000000975 dye Substances 0.000 description 49
- 239000000243 solution Substances 0.000 description 47
- 239000000306 component Substances 0.000 description 43
- 239000011541 reaction mixture Substances 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 38
- 239000000203 mixture Substances 0.000 description 37
- 239000000872 buffer Substances 0.000 description 32
- 230000035945 sensitivity Effects 0.000 description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 238000001514 detection method Methods 0.000 description 22
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 22
- 238000004401 flow injection analysis Methods 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 125000005647 linker group Chemical group 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 230000005855 radiation Effects 0.000 description 18
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 230000005284 excitation Effects 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000003993 interaction Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000007790 solid phase Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000011088 calibration curve Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000001007 phthalocyanine dye Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 239000013566 allergen Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 108010074605 gamma-Globulins Proteins 0.000 description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 206010056740 Genital discharge Diseases 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 230000009871 nonspecific binding Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- PBLZLIFKVPJDCO-UHFFFAOYSA-N 12-aminododecanoic acid Chemical compound NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000002860 competitive effect Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- QGKVXWDADKTZHW-UHFFFAOYSA-N azaporphyrin Chemical compound C1=C(N=2)C=CC=2C=C(N=2)C=CC=2C=C(N2)C=CC2=CC2=CNC1=N2 QGKVXWDADKTZHW-UHFFFAOYSA-N 0.000 description 5
- 238000003271 compound fluorescence assay Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 150000002605 large molecules Chemical class 0.000 description 5
- 230000002934 lysing effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 229940126585 therapeutic drug Drugs 0.000 description 5
- 230000036962 time dependent Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000006957 competitive inhibition Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000013389 whole blood assay Methods 0.000 description 4
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 3
- JNDZQWRVBINENC-UHFFFAOYSA-N 4-acetamido-n-[2-(ethylamino)ethyl]benzamide Chemical compound CCNCCNC(=O)C1=CC=C(NC(C)=O)C=C1 JNDZQWRVBINENC-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 239000001045 blue dye Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000813 peptide hormone Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- POWMMMXVDBMFMP-IYGQVCONSA-N 3-[(5r,10s,12r,13s,14s,17r)-12,14-dihydroxy-10,13-dimethyl-3-oxo-2,4,5,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)C2C([C@@]4(C)CCC(=O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 POWMMMXVDBMFMP-IYGQVCONSA-N 0.000 description 2
- RZVCEPSDYHAHLX-UHFFFAOYSA-N 3-iminoisoindol-1-amine Chemical compound C1=CC=C2C(N)=NC(=N)C2=C1 RZVCEPSDYHAHLX-UHFFFAOYSA-N 0.000 description 2
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 2
- CILXIKSQMBYYGP-UHFFFAOYSA-N 6-nitro-1h-pyrimidin-2-one Chemical compound OC1=NC=CC([N+]([O-])=O)=N1 CILXIKSQMBYYGP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960001066 disopyramide Drugs 0.000 description 2
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 2
- 229960002767 ethosuximide Drugs 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 238000000670 ligand binding assay Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960000808 netilmicin Drugs 0.000 description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229960000244 procainamide Drugs 0.000 description 2
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 2
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- AOBYOINVDHUHOB-UHFFFAOYSA-N 1,3-diiminoisoindole-2,4-dicarbonitrile Chemical compound C1=CC=C(C#N)C2=C1C(=N)N(C#N)C2=N AOBYOINVDHUHOB-UHFFFAOYSA-N 0.000 description 1
- KFLKTDAONDZLAN-UHFFFAOYSA-N 2-(n-phenylanilino)acetic acid Chemical compound C=1C=CC=CC=1N(CC(=O)O)C1=CC=CC=C1 KFLKTDAONDZLAN-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- ISCMYZGMRHODRP-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCN=C=N ISCMYZGMRHODRP-UHFFFAOYSA-N 0.000 description 1
- NGBYKZGOXFIONW-UHFFFAOYSA-N 4-(1,3-dimethyl-2,6-dioxo-7h-purin-8-yl)butanoic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(CCCC(O)=O)=N2 NGBYKZGOXFIONW-UHFFFAOYSA-N 0.000 description 1
- VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 1
- BGQNOPFTJROKJE-UHFFFAOYSA-N 5,6-diamino-1,3-dimethylpyrimidine-2,4-dione Chemical compound CN1C(N)=C(N)C(=O)N(C)C1=O BGQNOPFTJROKJE-UHFFFAOYSA-N 0.000 description 1
- KTCIKRABMGALCC-UHFFFAOYSA-N 5-(2-aminophenyl)-5-ethyl-1,3-diazinane-2,4,6-trione Chemical compound C=1C=CC=C(N)C=1C1(CC)C(=O)NC(=O)NC1=O KTCIKRABMGALCC-UHFFFAOYSA-N 0.000 description 1
- ZKLVPWCGMNVAQE-UHFFFAOYSA-N 5-(4-aminophenyl)-5-ethyl-1,3-diazinane-4,6-dione Chemical compound C=1C=C(N)C=CC=1C1(CC)C(=O)NCNC1=O ZKLVPWCGMNVAQE-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MQBPZGTUQWJZLO-UHFFFAOYSA-N N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=NC=C1C=C1C=CC4=N1 Chemical class N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=NC=C1C=C1C=CC4=N1 MQBPZGTUQWJZLO-UHFFFAOYSA-N 0.000 description 1
- JGQGDUURWUDSDW-UHFFFAOYSA-N N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=NN=C1C=C1C=CC4=N1 Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=NN=C1C=C1C=CC4=N1 JGQGDUURWUDSDW-UHFFFAOYSA-N 0.000 description 1
- 229910020886 NaBH2 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041316 Solvent sensitivity Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- FAAXSAZENACQBT-UHFFFAOYSA-N benzene-1,2,4,5-tetracarbonitrile Chemical compound N#CC1=CC(C#N)=C(C#N)C=C1C#N FAAXSAZENACQBT-UHFFFAOYSA-N 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- GRSTVVGJSKHCCS-UHFFFAOYSA-N bis(1h-imidazol-2-yl)methanone Chemical compound N=1C=CNC=1C(=O)C1=NC=CN1 GRSTVVGJSKHCCS-UHFFFAOYSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229940082657 digitalis glycosides Drugs 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- JHKWXZZEBNEOAE-UHFFFAOYSA-N dihydroxysilicon Chemical class O[Si]O JHKWXZZEBNEOAE-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
- JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 1
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 239000000990 laser dye Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- ZLQJVGSVJRBUNL-UHFFFAOYSA-N methylumbelliferone Natural products C1=C(O)C=C2OC(=O)C(C)=CC2=C1 ZLQJVGSVJRBUNL-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N n'-ethylethane-1,2-diamine Chemical compound CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 description 1
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- IBZUISWMZGLPKG-UHFFFAOYSA-N phosphoric acid azide Chemical compound [N-]=[N+]=[N-].OP(O)(O)=O IBZUISWMZGLPKG-UHFFFAOYSA-N 0.000 description 1
- XQZYPMVTSDWCCE-UHFFFAOYSA-N phthalonitrile Chemical compound N#CC1=CC=CC=C1C#N XQZYPMVTSDWCCE-UHFFFAOYSA-N 0.000 description 1
- 229920006391 phthalonitrile polymer Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000011546 protein dye Substances 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- ZOKPDCKJLXVQPL-UHFFFAOYSA-N pyridine;hydrochloride Chemical compound Cl.C1=CC=NC=C1.C1=CC=NC=C1 ZOKPDCKJLXVQPL-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical class N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000005049 silicon tetrachloride Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0838—Compounds with one or more Si-O-Si sequences
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/19—Rubella virus
Definitions
- the present invention relates to methods for deter ⁇ mining the presence or amount of antigenic substances in samples.
- the invention is directed to fluorescence 15 immunoassays using particular fluorescence dyes which are essentially free of aggregation and serum binding and, thus, are particularly suited for the measurement of antigenic substances in biological materials such as serum, plasma and whole blood.
- the determination of the presence or amount of anti ⁇ genic substances is commonly performed by immunoassay.
- Immunoassay techniques are based on the binding of the antigenic substance being assayed (the "target analyte") and a receptor for the target analyte. Either the target analyte or the receptor may be labeled to permit detec ⁇ tion. Various labels have been employed for use in
- immunoassays including radioisotopes, enzymes and fluorescent compounds.
- immuno ⁇ assays include competitive inhibition assays, sequential addition assays, direct "sandwich” assays, radioallergosorbent assays, radio- immunosorbent assays and enzyme-linked immunosorbent assays.
- the basic reaction underlying most immunoassays is the binding of certain substance, termed the "ligand” or “analyte", by a characteristic protein (receptor) to form a macromolecular complex.
- ligand or "analyte”
- receptor characteristic protein
- the unknown quantity of target analyte in the sample competes with a known amount of labeled target analyte for a limited number of receptor binding sites.
- the reagents usually consist of a labeled target analyte, such as an antigen, and a solid phase coupled receptor, such as an antibody.
- the antigen to be assayed competes with the labeled anti ⁇ gen for binding sites on the coupled antibodies.
- the concentration of target analyte present in the sample can be determined by measuring the amount of labeled target analyte — either "free” or “bound.” This is an indirect assay method where the amount of labeled antigen bound to the antibodies is inversely correlated with the amount of antigen in the test solution. Thus, low concentrations of target analyte in the sample will result in low concentra ⁇ tions of "free” labeled target analyte and high concentra ⁇ tions of "bound” labeled target analyte, and vice versa. The amount of "free” or "bound” labeled target analyte is measured using a suitable detector.
- Quantitative determi- nations are made by comparing the measure of labeled tar ⁇ get analyte with that obtained for calibrated samples containing known quantities of the target analyte.
- This method has been applied to the assay of a great number of different polypeptide hormones, enzymes and immunoglobu- lins. This method may also be used as a total liquid system. It is apparent to those skilled in the art that it is not absolutely necessary that the labeled analyte be iden ⁇ tical to the unlabeled target analyte.
- the reaction between labeled and unlabeled analytes may be considered to be competitive for the receptor binding sites; and the reaction will still provide quantitative answers, provid ⁇ ing the difference in affinity of the analytes is not too great.
- competition occurs in a system consisting of labeled analyte, unlabeled analyte, and receptor depends on the nature of the labeled analyte and the specificity of the receptor.
- the reagents used are the same as in the competitive inhibition assay described above. However, instead of incubating them at the same time, the unlabeled antigen is first incubated with the antibody, then the labeled antigen is added.
- Direct immunoassay systems are also known in the art.
- Such assays also termed “immunometric” assays, employ a labeled receptor (antibody) rather than a labeled analyte (antigen) .
- antibody labeled receptor
- analyte analyte
- Immunometric assays are well- suited to the detection of antigenic substances which are able to complex with two or more antibodies at the same time. In such "two-site” or “sandwich” assays, the anti ⁇ genic substance has two antibodies bound to its surface at different locations.
- an antibody bound to a solid phase is first con- tacted with the sample being tested to form a solid phase antibody:antigen complex. After incubation, the solid support is washed to remove the residual sample, including unreacted antigen, if any. The complex is then reacted with a solution containing a known amount of labeled anti ⁇ body. After a second incubation to permit the labeled antibody to complex with the antigen bound to the solid support through the unlabeled antibody, the solid support is washed to remove unreacted labeled antibody.
- the assay can be used as a simple "yes/no" assay to determine whe ⁇ ther the antigen is present.
- Quantitative determinations can be made by comparing the measure of labeled antibody with that of calibrated samples containing known quanti ⁇ ties of antigen.
- "Simultaneous” and “reverse” sandwich assays are also known in the art.
- a simultaneous assay involves a single incubation step, both the labeled and unlabeled antibodies being added at the same time.
- a reverse assay involves the addition of labeled antibody followed by addition of unlabeled antibody bound to a suitable solid support.
- the sandwich technique can also be used to assay antibodies rather than antigens.
- Such an assay uses as a first receptor an antigen coupled to a solid phase. The antibodies being tested are first bound to the solid phase-coupled antigen. The solid phase is then washed, and then labeled anti-antibody (second receptor) is added.
- the radioallergosorbent technique is a method for the determination of antigen-specific IgE.
- the method uses a solid phase coupled antigen and an immunoabsorbent purified antibody labeled with a radioactive isotope.
- the method is used to detect reaginic antibodies against vari ⁇ ous antigens which elicit allergic reactions (allergens) .
- the reaginic antibodies react with allergen bound to a solid matrix. After washing of the solid phase, the allergen-bound reaginic antibodies are detected by their ability to bind labeled antibodies against IgE.
- a variant of RAST can be used for the determination of allergens.
- the allergen to be tested is incubated with the reaginic antibody.
- the mixture is then tested with RAST using the same allergen coupled to the solid matrix.
- the allergen in solution reacts with the reaginic antibodies and thus inhibits the binding of these antibodies to the solid phase-coupled allergen.
- RIST radioimmunosorbent technique
- the solid support is sensitized with anti-IgE and increasing amounts of labeled IgE are added to determine the maximum amount of IgE that can bind.
- a quantity of labeled IgE equivalent to approximately 80% of the plateau binding is chosen.
- this amount of labeled IgE is mixed with the serum containing the IgE to be tested.
- the test IgE competes with the labeled IgE. The more IgE present in the test serum the less the amount of labeled IgE that binds.
- RIST radioimmunosorbent technique
- the above immunoassay methods can be applied to the assay of many different biologically active substances.
- substances include haptens, hormones, gamma globu ⁇ lin, allergens, viruses, virus subunits, bacteria, toxins such as those associated with tetanus and animal venom, and many drugs.
- Similar techniques can be used in non- immunological systems with, for example, specific binding proteins.
- a separa- tion step is required to separate "free" from "bound" labeled target analyte.
- Such assays which require a separation step, are called “heterogeneous” assays. If the properties of the label are altered in some way when it is bound, no separation step is required, and the immunoassay is termed "homogeneous.”
- Both the specificity and sensitivity of an immunoassay depend on the characteristics of the binding interaction between the target analyte and the receptor involved. For example, the reaction must be specific for the analyte to be measured and the receptor used should not bind to any other structurally related compounds. In addition, by choosing a receptor with a high affinity for the target analyte, the sensitivity can be increased.
- the label used to monitor the assay affects the sensitivity of an immunoassay. Labels currently used for immunoassay of target analytes in biological fluids include radioisotopes (radioimmunoassay, RIA) , enzymes
- RIAs are sufficiently sensitive for use in detection in low concentrations of analytes because of their low background. They are disadvantageous in that they are heterogeneous, thus requiring a separation step before measurement of the bound and/or free portions of labelled target analyte. RIAs involve the inconvenience and haz ⁇ ards associated with the handling and disposing of radio ⁇ isotopes. In addition, they are labor intensive and have a short shelf life due to the half-lives of radiolabels and to chemical damage produced by the emitted radiation. EIAs have the advantage of increased signal over background, longer shelf life, lack of radiation hazards, and homogeneity.
- CIAs Chemiluminescent immunoassays
- CIAs are disadvanta- geous because they are heterogeneous, require expensive reagents, and are expensive to automate. See generally Boeckx, R.L., "Luminescence: A New Analytical Tool for Therapeutic Drug Monitoring,” in P. Moyer et al. , Applied Therapeutic Drug Monitoring, American Association of Clin- ical Chemistry (1984) .
- FIAs use fluorescent molecules as labels. Fluores ⁇ cent molecules (fluorophores) are molecules which absorb light at one wavelength and emit light at another wave ⁇ length. See Burd, J.F., "Fluoroimmunoassay — Application to Therapeutic Drug Measurement,” in P. Moyer et. al. , App ⁇ lied Therapeutic Drug Monitoring, American Association of Clinical Chemistry (1984) . Typically, an excitation pulse of radiation is directed onto or into a sample, followed by fluorescence of the sample, and the detection of the fluorescence radiation.
- FIAs may be either heterogeneous or homogeneous.
- homogeneous assays are usually simpler to perform and are thus, more amenable to automation. How ⁇ ever, previously known homogeneous FIAs are less sensitive than heterogeneous FIAs because high background can limit sensitivity.
- the heterogeneous FIA procedures can detect smaller amounts of analyte than present homogenous FIAs, but only because the separation and washing steps in the assays serve to eliminate background interference from biological substances.
- solid phase fluorescent assays the solid support can limit sensitivity at the wavelengths of presently used fluors. In many cases the support itself will fluoresce at wavelengths of commonly used fluors such as fluorescein (493 nm) .
- FIAs also offer the advantage of using stable reagents.
- Another assay method uses enzyme-enhanced fluores- cence technology which combines microparticle capture and antigen-antibody reaction with an enzyme rate reaction using a fluorescent enzyme substrate. The rate reaction is monitored by steady state fluorometric measurement.
- an enzyme-enhanced fluorescence assay the analyte in question is "captured" by an antibody bound to a solid phase and the solid phase is washed. An enzyme is then bound to the captured analyte using an enzyme-anti analyte conjugate. Excess reactants are washed away and the amount of enzyme is measured by the addition of a non- fluorescent substrate. As the enzymatic reaction pro ⁇ ceeds, the non-fluorescent substrate is converted to the fluorescent product.
- an alkaline phospha- tase-labeled antibody can be used to catalyze the hydro ⁇ lysis of 4-methylumbelliferyl phosphate substrate to the fluorescent product methylumbelliferone.
- the rate at which the fluorescent product is generated is directly proportional to the concentration of analyte in the test solution.
- Enzyme-enhanced fluorescence assays like EIAs, have the disadvantages associated with enzymes. As discussed above, fluorescence is a phenomenon exhibited by certain substances, which causes them to emit light, usually in the visible range, when radiated by another light source. This is not reflection, but crea ⁇ tion of new light. Current commercially available assay methods use fluorescein, which emits green light when radiated by a light source containing blue light.
- fluorescein In addition to fluorescing, fluorescein (and other fluorophores) emit polarized light. That is, the light emitted has the same direction of polarization as the incident polarized light, if the fluorescein molecule is held fixed wit its transition moment parallel to the electric field of the excitation.
- the amount of polariza- tion in the emission can be defined in terms of the inten ⁇ sity of the horizontally and vertically polarized light, as follows:
- Ih intensity of horizontally polarized emission
- the maximum, or limiting value of polarization, for fixed, randomly oriented molecules is 0.5 (Po) .
- a second equation (the Perrin equation) defines polarization in terms of physical parameters and Po:
- Rotation relaxation is further defined for spherical molecules as
- FPIA fluor ⁇ escence polarization immunoassay
- the relationship between polarization and drug con- centration can be determined by creating a standard, or calibration, curve. This is done by running an assay using a range of known drug concentrations, from the lowest to highest expected concentrations, and plotting the resulting values of polarization. Thereafter, for a given value of polarization, the drug concentration can be determined from the standard curve.
- One advantage of the polarization technique is the elimination of a step to separate unbound probe. Although the unbound tracer is not physically eliminated from the samples in FPIA, its contribution is readily assessed by the. polarization.
- fluorometry is capable of being the most sensitive of all analytic tools as it is possible to detect single photon events.
- a problem which has plagued fluorescence immunoassays has been discriminating the fluorescent signal of interest from background radiation.
- the intensity of signal from background radiation may be up to 10,000 times larger than the intensity of the fluorescent signal of interest.
- the problem of background detection is particularly pronounced in assay of biological samples.
- Many of the current fluorescence assays use the fluorescent molecule, fluorescein. Fluorescein has an excitation maximum of 493 nm, and there are numerous substances in biological fluids with overlapping excitation and emission similar to fluor ⁇ escein.
- a second technique attempting to * discriminate the desired fluorescent signal from the background is the so called time gating approach.
- the fluorescent signal is observed in a short time window after the excitation.
- the time window may be varied both in its length and in its starting time.
- the detected radiation may be observed at the maximal time for detection sensitivity.
- this technique has used a fluorophore of very long decay time (such as 1,000 nanoseconds) to allow the background fluorescence to substantially decay before detection of the fluorescent signal of interest.
- long decay time fluorophores require longer times for overall analysis. Due to the long decay time, the light source cannot be pulsed rapidly to collect: data, thus requiring additional time for final analysis.
- transient state fluorescent analysis utilizes a single, relatively high power pulse which excites the fluorophore.
- the transient state is typically monitored by a high speed photomultiplier tube by monitoring the analog signal representative of current as a function of time.
- Single pulse systems require sufficiently high power to excite a large number of fluorescent molecules to make detection reliable.
- the other principal format for transient state fluorescent analysis is a digital format which utilizes repetitive excitation pulses.
- pulses of relatively short, typically nanosecond duration, light with power in the microwatt range are repetitively supplied to the sam- pie at rates varying from 1 to 10,000 Hz.
- the excitation source is a lamp, such as a Xenon-lamp.
- the decay curve is measured digitally by deter ⁇ mining the time to receipt of a photon.
- One commercially available system uses repetitive pulses (such as at 5,000 Hz) and pulses the photomultiplier tube at increasingly longer times after the flash in order to obtain a time dependent intensity signal. Detection in such systems has proved to be very time consuming and insensitive. A single analysis can take on the order of one hour, even at relatively high fluorescable dye concentrations (e.g. , 10 "6 M) .
- an object of the present invention is to provide improved processes for assay of antigenic substances. More speci ⁇ fically, the present invention provides fluorescence assays which allow the detection of low levels of anti ⁇ genic substances in biological samples such as serum, plasma and whole blood. The present invention also pro ⁇ vides homogeneous fluorescence assays which allow rapid and accurate determination of low levels of antigenic substances in biological samples.
- the present invention is directed to methods for determining the presence or amount of a target analyte in a sample by using, as a label for the target analyte or a receptor which is capable of specifically recognizing the target analyte, a fluorophore moiety comprising a lumi ⁇ nescent substantially planar molecular structure coupled to two stabilizing polyoxyhydrocarbyl moieties, one located on either side of the planar molecular structure.
- target analyte is meant the antigenic substance being assayed, for example an antigen.
- receptor is meant a molecule or molecular component capable of specifically recognizing the target analyte.
- an antibody may be a receptor for an antigen.
- detectable labels or marker components are advantageous in that these labels have substantially the same intensities of parallel and perpen ⁇ dicular components of transient state fluorescence emis ⁇ sion in the presence and absence of biological fluids such as serum.
- assay methods using these labels are capable of detecting low concentrations of target analyte in biological fluids.
- the methods of the present invention are particularly suitable for use with the improved fluorescence detection system described in commonly assigned U.S. Patent Applica- tion entitled “Fluorometer Detection System, " Lyon & Lyon Docket No. 195/129, filed concurrently herewith.
- the present invention is directed toward competitive inhibition assay procedures utilizing particular labels.
- the present invention is directed to a method of determining the presence or amount of a target analyte by contacting a sample sus ⁇ pected of containing the target analyte with a known quantity of added target analyte or analog thereof linked to a fluorescent probe which includes a detectably labeled marker component made up of a fluorophore moiety which includes a luminescent substantially planar molecular structure coupled to two solubilizing polyoxyhydrocarbyl moieties, one located on either side of the planar mole- cular- structure; contacting the sample with a receptor capable of specifically recognizing the target ligand; and determining either the amount of fluorescent probe bound to receptor or free fluorescent probe.
- the amount of bound or free fluorescent probe in the unknown samples may be compared with blank samples and samples containing known amounts of target analyte.
- the resultant mixture of sample, fluorescent probe and receptor is diluted before measurement of the amount of bound and/or free fluorescent probe.
- the dilution step allows for greater sensitivity of the assay. Particularly preferred are dilutions of 2-fold to 100-fold, preferably about 7-fold to about 50-fold, and more preferably about 35-fold.
- the present invention provides an improvement in immunoassay procedures which utilize a label for either the target analyte (or analog thereof) or the receptor.
- the improvement is the use of a fluorophore moiety comprising a luminescent substantially planar mole ⁇ cular structure coupled to two solubilizing polyoxyhydro- carbyl moieties, one located on either side of the planar molecular structure.
- Assays using this type of label are advantageous in that they are free of serum binding and aggregation and are therefore, especially suitable for testing biological samples such as serum, plasma, whole blood and urine.
- the present invention provides a method for performing a "sandwich” or "two-site” immuno ⁇ assay comprising the steps of:
- a sandwich-type assay may be either a heterogeneous assay or a homogeneous assay. If it is heterogeneous, it may incorporate the additional step of separating the solid carrier from the unreacted labeled first receptor. Homogeneous assays are generally preferred because they are more rapid. In another embodiment, the assay may incorporate the additional step of relating the amount of labeled first receptor measured in the unknown sample to the amount of labeled first receptor measured in a control sample free of said target analyte, or to the amount of labeled first receptor measured in samples containing known quantities of target analyte. In another aspect, the present invention provides a method for a simultaneous sandwich-type assay comprising a method for determining the presence or amount of a target analyte in a sample comprising the steps of :
- the present invention provides a method for a simultaneous sandwich-type assay comprising a method further comprising the step of relating the amount of labeled first receptor measured to the amount of labeled first receptor measured for a control sample free of said target analyte, or relating to the amount of labeled first receptor measured with the amount of labeled first receptor measured in samples containing known amounts of target analyte.
- the present invention provides a sandwich-type fluorescence immunoassay method for measure ⁇ ment of a target analyte which is capable of recognizing two different receptors independently without mutual interference. The method utilizes two receptors, each of which is labeled with a different dye.
- one receptor is labeled with a first dye having absorption and emission maxima of 680 nm and 690 nm, respectively, and the other receptor is labeled with a second dye having absorption and emission maxima of 695 and 705 nm, respec ⁇ tively.
- Detection and quantitation of the analyte can be made using either steady state or transient state measure- ments. In either case, for the example given, excitation would be at 680 nm and detection would be at 705 nm.
- This type of assay is based on energy transfer and is advan ⁇ tageous in that it is homogeneous.
- the present invention is directed to immunoassay of biological fluids, including serum, plasma, whole blood and urine.
- red blood cells in whole blood are lysed prior to assay of whole blood samples.
- Preferred methods of lysing red blood cells include addition of stearyl-lysolecithin, palmitoyl-lysolecithin and myristoyl lysolecithin.
- the target analyte may be an antigen, a hapten or an antibody; and the receptor may be an antigen or antibody.
- the antibody may be polyclonal or monoclonal. Preferably, the antibody is a monoclonal antibody.
- Monoclonal antibodies useful in the present invention may be obtained by the Kohler & Milstein method reported in Nature 256:495-497 (1975) . Alternatively, they may be produced by recombinant methods. Science 246:1275-1281 (1989) .
- the target analyte is a drug or a metabolite of a drug.
- the drug may be a steroid, hormone, antiasthmatic, antineoplastic, antiarrhythmic, anticonvul- sant, antiarthritic, antidepressant, or cardiac glycoside.
- examples of such drugs include digoxin, digitoxin, theo- phylline, phenobarbital, thyroxine, N-acetylprocainamide , primidone, amikacin, gentamicin, netilmicin, tobramycin, carbamazepine, ethosuximide, valproic acid, disopyramide, lidocaine, procainamide, quinidine, ethotrexate, ami- triptyline, mortriptyline, imipramine, desipramine, van- comycin, and cyclosporine.
- the drug is digoxin.
- the target analyte is a pep ⁇ tide, for example, a peptide hormone such as luteinizing hormone, follicle stimulating hormone, human choriogonado- tropin, thyroid stimulating hormone, angiotensin I, angio- tensin II, prolactin or insulin.
- the peptide may also be a tumor marker such as carcinoembryonic antigen.
- the peptide may be a virus or portion thereof, for example, rubella virus or a portion thereof.
- the methods of the present invention provide ways of measuring target analytes in concentrations of from about 1 x 10 "5 M/L to about 1 x 10 "13 M/L, and particularly in the concentration range of from about 1 x 10" 9 M/L to about 1 x 10 "12 M/L.
- the present methods allow measurement in the range from about 5 x 10" 9 M/L to about 5 x 10" 12 M/L, and particularly, concentrations of from about 1 x 10" 10 M/L to about 5 x 10 "10 M/L.
- the present methods allow measurement in the range of from about 1 x 10 "11 M/L to about 1 x 10 "12 M/L.
- the measurement of amount of fluorescent probe — bound or free or both — can be determined by measuring steady-state fluorescence or by measuring transient state fluorescence.
- the wavelength of light measured is greater than about 500 nm, preferably greater than about 650 nm, and more preferably greater than about 680 nm or 690 nm. Because the transient state detection system utilizes a laser diode, it is necessary for the dyes to have excitation maxima matched to the diode output wavelengths. Dyes have been made available to match other commercially available laser diodes have output wavelengths of 680, 690, 720, 750, or 780 nm.
- the wavelength of the light measured may be greater than about 680 nm, 690 nm, 720 nm, 750 nm or 780 nm. The further into the red region of the spectrum one moves, i.e. , the greater the wavelength, the greater signal enrichment there is over background.
- detection and quantitation is performed using transient state measurement.
- Transient state energy transfer offers improved measurements due to optimization of the wavelengths of absorption and emis ⁇ sion, as well as due to optimization of the decay times of the first and second dyes. Such optimization allows removal of Rayleigh and Raman scattering, and achieving the best compromise between efficiency of transfer and the undesired direct excitation of the second dye by the first dye.
- the present invention is directed to immunoassays using detectably labelled marker components which comprise a fluorophore moiety which comprises a substantially planar macrocyclic multidentate ligand coordinated to a central atom and two solubilizing poly ⁇ oxyhydrocarbyl moieties, one linked on either side of the plane of the multidentate ligand to the central atom.
- detectably labelled marker components which comprise a fluorophore moiety which comprises a substantially planar macrocyclic multidentate ligand coordinated to a central atom and two solubilizing poly ⁇ oxyhydrocarbyl moieties, one linked on either side of the plane of the multidentate ligand to the central atom.
- the present invention is directed to immunoassays using a marker component compris ⁇ ing a fluorophore moiety which comprises a substantially planar multidentate macrocyclic ligand coordinated to a central atom capable of coordinating with two axial lig ⁇ ands which are coordinated to the central atom on either side of the macrocyclic ligand.
- Marker components used in the immunoassays of the present invention comprise a macrocyclic multidentate ligand having two solubilizing polyoxyhydrocarbyl moieties one located on either side of the plane of the multiden ⁇ tate ligand exhibit no detectable non-specific binding to serum components, and exhibit no detectable solvent sensi ⁇ tivity. These marker components also exhibit enhanced decay times which approach their natural (fluorescent) lifetimes.
- fluorophores which produce fluorescent light efficiently, i.e. , which are characterized by high absorbitivity at the appropriate wavelength and high fluorescence quantum yields.
- preferred fluorophores have measured fluorescence decay times on the order of at least 2 nanoseconds and exhibit a high degree of fluorescence polarization.
- Preferred solubilizing polyoxyhydrocarbyl moieties include water soluble carbohydrates such as glucose, sucrose, maltotriose, and the like; water soluble car ⁇ bohydrate derivatives such as gluconic acid and mannitol and oligo saccharides; and water soluble polymers such as polyvinylpyrrolidone, poly(vinylalcohol) , poly(ethyleni- mine) , polyacrylic acid, polyacrylamide, ethylene oxide copolymers such as Pluronic (a propylene oxide copolymer, available from BASF) and Tetronic (BASF) polyol surfac ⁇ tants; and polyethers, including water soluble polyoxy- alkylene polymers, particularly poly(ethylene glycol) (“PEG”) and poly(ethylene glycol) derivatives such as poly(ethylene glycol) methyl ether, poly(ethylene glycol) silicon derived ethers and the like.
- PEG poly(ethylene glycol)
- the present invention is directed to immunoassays using marker components comprising a fluoro ⁇ phore moiety which comprises a substantially planar, mul- tidentate macrocyclic ligand coordinated to a central atom capable of coordinating with two axial ligands and two polyoxyhydrocarbyl moieties which are attached as axial ligands to the central atom.
- Suitable central atoms are those to which may coordinate two axial ligands and which are not of high enough atomic number to cause extensive fluorescence quenching by transition to the triplet state.
- Preferred elements for the central atom include silicon, germanium, phosphorus, and tin, especially preferred are silicon and germanium.
- these marker components may be used as labels for labelling an analyte, antigen, antibody or other molecule.
- These marker compo- nents may be optionally functionalized so as to include a linker arm which allows the marker component to be linked to the analyte, antigen, antibody or other molecule.
- linker arms which may be suited to this pur- pose.
- the marker component is linked to the analyte, antigen, antibody or other molecule using conventional techniques.
- the present invention is also directed to the use of divalent peptide derivatives as analogs for large mole- cules in immunoassays.
- a divalent hapten consisting of two epitopes of the same specificity con ⁇ nected by a linker about 10 nm long is used to bind to a single antibody molecule, requiring approximately 26 residues.
- the present invention also includes assay methods of involving cellular receptors located on the plasma mem ⁇ brane or isolated from cytosols and synthetic ligand binders obtained by molecular imprinting.
- the present invention also provides particular fluor ⁇ escent probes for use in immunoassays, for instance, see Examples 3 and 11-18 below.
- target analyte refers to the compound or compound to be measured in an assay which may be any compound for which a receptor naturally exists or can be prepared which is mono- or polyepitopic, antigenic or haptenic, a single or plurality of compounds which share at least one common epitopic site or a receptor.
- analog of a target analyte is meant a compound or com ⁇ pounds capable of competing with the target analyte for binding to a receptor.
- axial ligand refers to a substituent which, together with a macrocyclic ligand, forms a coordination complex with a central atom.
- the axial ligand lies normal to the plane described by the macro ⁇ cyclic ligand.
- fluorescent probe refers to a marker component comprising a fluorophore moiety which is bonded to or coordinates either directly or via a linker arm to an analyte, antigen, hapten, antibody or other molecule which is used in an assay, such as a fluoroimmunoassay to determine the presence of and/or quantitate a substance of interest.
- solvent sensitivity refers to changes in the fluorescence behavior of a molecule depending on the solvent system in use, most notably referring to differ ⁇ ences in fluorescence behavior in aqueous solution in comparison with organic solvents (such as DMF) .
- organic solvents such as DMF
- Fluorescence intensity is related to sample concen ⁇ tration and the intensity of the exciting radiation.
- the fluorescence intensity of a particular dye can be corre- lated to its characteristic light absorptivity (extinction coefficient) and fluorescence quantum efficiency, as well as environmental factors.
- binding pair refers to two dif ⁇ ferent molecules (or compositions) wherein one of the molecules has an area on the surface or in a cavity which specifically recognizes and binds to a particular spatial and polar organization of the other molecule or molecular complex involving other molecules.
- binding partner refers to a molecule or molecular complex which is capable of specifically recog ⁇ nizing or being recognized by a particular molecule or molecular complex.
- bound refers to the condition in which a binding interaction has been formed between a molecule and its specific binding partner.
- decay time is the time which must elapse in order for the concentration of excited molecules to decrease from its initial concentration to 1/e of that value.
- receptor refers to a molecule or molecular complex which is capable of specifically recognizing or being recognized by a target analyte or analog thereof.
- Fig. 1 depicts an HPLC analysis of crude caged dicar- boxy silicon phthalocyanine dye preparation.
- Fig. 2 shows the absorbance of caged dicarboxy sili ⁇ con phthalocyanine dye in various solvents.
- Fig. 3 describes the Diatron Analog System.
- Fig. 4 depicts the decay time for caged dicarboxy silicon phthalocyanine dye.
- Fig. 5 shows serum interactions of purified caged dicarboxy silicon phthalocyanine dye.
- Fig. 6 depicts the absorbance spectrum of caged dicarboxy silicon phthalocyanine dye-C12 linker.
- Fig. 7 depicts the polarization of caged dicarboxy silicon phthalocyanine dye-C12 linker at 680 nm.
- Fig. 8 depicts the polarization of caged dicarboxy silicon phthalocyanine dye-C12 linker at 690 nm.
- Fig. 9 depicts an HPLC Chromatograph of caged dicar- boxy silicon phthalocyanine digoxin probe.
- Fig. 10 depicts the structure of caged dicarboxy silicon phthalocyanine digoxin probe.
- Fig. 11 shows the absorbance spectrum of caged dicarboxy silicon phthalocyanine digoxin probe in methanol.
- Fig. 12 shows the absorbance spectrum of caged dicarboxy silicon phthalocyanine digoxin probe in FPIA buffer.
- Fig. 13 shows the decay time for caged dicarboxy silicon phthalocyanine digoxin probe.
- Fig. 14 shows the linearity of intensity for caged dicarboxy silicon phthalocyanine digoxin probe.
- Fig. 15 shows serum/urine interactions for caged dicarboxy silicon phthalocyanine digoxin probe.
- Fig. 16 depicts a comparison of TDx ® and FAST-60 calibration curves.
- Fig. 17 depicts the correlation of digoxin samples assayed by TDx ® and FAST-60.
- Fig. 18 depicts the effect of dilution jump on non-specific binding.
- Fig. 19 depicts a digoxin probe-serum calibration curve.
- Fig. 20 depicts a calibration curve for a high sensi ⁇ tivity digoxin assay.
- Fig. 21 describes the FAST-60 digoxin assay procedure.
- Fig. 22 depicts digoxin correlation — TDx ® Serum vs. FAST-60 Whole Blood.
- Fig. 23 depicts digoxin correlation — Stratus ® Serum vs. FAST-60 Whole Blood.
- Fig. 24 depicts digoxin correlation — ' FAST-60 Serum vs. FAST-60 Whole Blood.
- Fig. 25 depicts digoxin correlation — TDx ® Serum vs. FAST-60 Serum.
- Fig. 26 depicts digoxin correlation — Stratus ® Serum vs. FAST-60 Serum.
- Fig. 27 depicts the structure of caged dicarboxy silicon phthalocyanine digitoxin probe.
- Fig. 28 depicts the structure of caged dicarboxy silicon phthalocyanine theophylline probe.
- Fig. 29 depicts the structure of caged dicarboxy silicon phthalocyanine phenobarbital probe.
- Fig. 30 depicts the structure of caged dicarboxy silicon phthalocyanine thyroxine probe.
- Fig. 31 depicts the structure of caged dicarboxy silicon phthalocyanine n-acetylprocainamide probe.
- Fig. 32 depicts the structure of caged dicarboxy silicon phthalocyanine primidone probe.
- Fig. 33 depicts the structure of caged dicarboxy silicon phthalocyanine phenytoin probe.
- Fig. 34 depicts a rubella antibody calibration curve for a sandwich assay.
- Fig. 35 depicts a rubella peptide calibration curve for an inhibition assay.
- Fig. 36 depicts a rubella antibody calibration curve for direct polarization.
- the present invention provides fluorescence immuno ⁇ assay methods which have dramatic increases in sensitivity over previous methods, which can be easily performed 5 because they require no separation step, and which can be used to detect and quantitate low levels of target analyte in biological samples such as serum, plasma, whole blood and urine.
- the FIAs of the present invention may be per ⁇ formed in small samples. For example, a digoxin assay may
- FIA 10 be performed on a 20 ⁇ l sample of serum, plasma or whole blood, and the assay may be performed in about five min ⁇ utes.
- the ability to perform FIAs on whole blood samples is particularly significant because it allows assays to be performed at locations closer to the patient, such as
- the present invention provides methods for FIAs which
- the probes used in the method of the invention have excitation (and emission) wavelengths greater than about 650 nm, preferably greater than 680 nm. This wavelength shift into the infra-red
- the probes used in the present assay methods have low dielectric constants, which applicants believe tend to increase the Van der Waal interactions and hydrogen bond ⁇ ing, thus accelerating the antigen/antibody reaction. In addition, applicants believe that these probes compete for the water of hydration, thus potentiating the antigen/ antibody reaction. In other words, the probes not only substantially decrease non-specific bindings to serum components, but applicants believe that they potentiate the immunochemical reaction.
- the present invention provides a further increase in sensitivity by measuring transient state fluorescence rather than the steady state signal.
- the signal In the steady state mode the signal is constant over time enabling the determination of one experimental parameter, e.g. , the polarization or the anisotropy, both of which are related to molecular rotational motion.
- the transient state mode the signals vary in a systematic way with time. This varia ⁇ tion represents a complex summation of the rates of decay and of molecular rotation as it changes from moment to moment in time.
- the increase in sensitivity from transient state measurements stems from two sources. First, that portion of the background due to Rayleigh and Raman scattering disappears in about 10 "15 sec and so is cleanly removed before the transient state measurements start. This portion of background is normally an important part of the total in steady state measurements.
- the tran ⁇ sient state measurements provide an additional powerful means to discriminate between the desired signal and the remaining fluorescence portion of the background. This discrimination rests upon the time dependence of the polarized components in the fluorescence decay and makes it possible to extract the desired signal only, simultane ⁇ ously on the basis of the rate of decay of the excited state and the rate of decay of the rotational distribution imprinted by the excitation.
- transient state methods allow signal to be distinguished from background in ways not possible with steady state information alone.
- the probes exhibit a high degree of polarization, necessary for mix and read (homogeneous) fluorescence polarization assays. This increase in polarization translates into increased sensitivity.
- the methods of the present invention are particularly useful when used with a time-correlated transient state detection system, as described in commonly assigned Studholme, et. al..
- the system uses a laser diode which can be modulated at very high frequencies, e.g.. 10 MHz rate, and exhibits high output power. Typically the laser "on" time is approximately 2-3 nanoseconds. Photons from the solution are detected using a photomultiplier tube (PMT) operating in a single photon counting mode.
- PMT photomultiplier tube
- the photon event along with the relative time of the photon event as compared with the laser pulse time is determined.
- a histogram of frequency of photons as a function of time is generated.
- Data obtained in this manner can be analyzed as described in Dandliker et, al. , U.S. Patent No. 4,877,965, entitled “Fluorometer” or as described by Studholme, et al. , U.S. Patent Application entitled, "Fluorometer Detection System,” Lyon & Lyon Docket No. 195/129, filed concurrently herewith.
- the methods of the present invention also include the use of divalent peptide derivatives as analogs for large molecules in immunoassays. Both polyclonal and monoclonal antibody molecules are divalent. Due to the "chelate effect, " the binding of a low molecular weight mimic or analog of a larger molecule will be stronger and dissoci- ation from the antibody will be slower if both antibody binding sites are utilized in the bonding. It is within the scope of the present invention to arrange the struc ⁇ ture of the peptide analog to have two identical sequences joined together by a linker of suitable length so as to place the two peptide sequences, in their normal config ⁇ uration in solution, in the most favorable position for reaction with the two sites on the same antibody molecule.
- divalent peptide derivatives as analogs for large molecules in immunoassays is preferred in solution, especially in conjunction with dilution jump, due to the tighter binding afforded by the "chelate effect, " resulting in an increase in the sensitivity of the immunoassay.
- a divalent hapten consisting of two epitopes of the same specificity connected by a linker about 10 nm long is used to bind to a single antibody molecule. Taking into account the bond distances and angles for simple peptides (L. Pauling, The Nature of the Chemical Bond, Cornell University Press (1960) , p. 498) and assuming a length of 0.380 nm per amino acid residue, this would require approximately 26 residues for a 10 nm length.
- One approach for designing a divalent hapten with such a linker is to synthesize the epitope with a 13 resi- due linker terminating in a primary amino group. This peptide is then reacted with the bis (3-isocyanatopropyl- dimethylsilyl) derivative of dihydroxysilicon phthalocya ⁇ nine. The resulting structure has the phthalocyaninine moiety with two axial substituents, one on either side of the molecular plane, each consisting of a thirteen residue peptide linker leading to the peptide epitope. The mole ⁇ cular plane of the dye moiety is perpendicular to the direction of the linker.
- the dye moiety may be located midway between the two arms of the Y-shaped antibody molecule.
- the polarization changes obtainable with this type of structure may not be as great as if the dye were linked through a peripheral rather than an .axial bond, and the absence of PEG may result in non-specific binding.
- the dye moiety is held close to the antibody surface between the two Fab fragments after binding, it may prove to be quite protected and rotate with the long ⁇ est rotational decay time of the antibody (since the molecular plane of the dye may lie parallel to the long axis of the antibody) .
- a divalent peptide hapten may be designed to utilize the PEG protected dye linked through a peripheral carboxyl to an amino group on the linker or on one of the peptide epitopes, e.g. , the linkage could be the e-amino group of a lysine residue located approxi ⁇ mately midway on an interconnecting chain between the two peptide epitopes.
- Immunoassays depend upon the strong and selective binding of some analyte of interest to antibody specific for that analyte.
- Other molecular structures that have similar strong and selective binding for such an analyte can serve equally well in designing an assay and such structures may have some inherent advantages over antibody.
- molecules which may have desirable properties in this context include cellular receptors located on the plasma membrane or isolated from cytosols and synthetic ligand binders obtained by a process known as "molecular imprinting.
- the sensitivity of a ligand binding assay depends upon the binding affinity of association constant (K) of the reaction between the analyte and the binding molecule.
- K association constant
- these Ks are of the order of 10 9 M "1 .
- the binding constant for diazepam was found to be about 10 8 M "1 (Vlatakis et, al. , Nature 361: 645-647 (1993)).
- the highest Ks for antibody binding are of the order of 10 12 M "1 for lig ⁇ ands such as fluorescein and digoxin.
- the present invention includes methods of involving cellular receptors located on the plasma mem ⁇ brane or isolated from cytosols and synthetic ligand binders obtained by molecular imprinting.
- Suitable fluorophore moieties comprise a luminescent substantially planar molecular structure.
- Preferred central atoms are elements which may form octahedral coordination complexes containing two ligands with a trans or axial orientation, on either side and perpendicular to the planar macrocyclic ligand.
- the central atom should not have too high atomic number (about 30 or less) so that fluorescence is not diminished through coupling interaction with orbitals of the central atom.
- Preferred multidentate ligands include nitrogen- containing macrocycles which have conjugated ring systems with pi-electrons. These macrocycles may be optionally substituted, including substitution on bridging carbons or on nitrogens. Suitable macrocycles include derivatives of porphyrins, azaporphyrins, corrins, sapphyrins and por- phycenes and other like macrocycles which contain elec ⁇ trons which are extensively delocalized.
- an especially preferred class of macrocycles comprise porphyrin derivatives, and azaporphyrin deriva- tives (porphyrin derivatives wherein at least one of the bridging carbons is replaced"by a nitrogen atom) .
- Azapor ⁇ phyrin derivatives include derivatives of mono-, di- and triazaporphyrin and porphyrazine.
- These macrocycles may optionally have fused aromatic rings.
- These azaporphyrin derivatives include phthalocyanine, benzotriazaporphyrin and naphthalocyanine and their derivatives.
- azaporphyrin derivatives which exhibit a high degree of polarization, that is, those which emit strongly polarized light.
- macrocycles having lower degrees of symmetry preferably having lower symmetry than D 4h .
- One preferred group includes macrocycles having at least one fused aromatic ring.
- preferred macro- cycles include azaporphyrin derivatives having fused aromatic rings at positions which result in decreased symmetry.
- Preferred classes of azaporphyrin derivatives comprise derivatives of monoazaporphyrin, diazaporphyrin, and triazaporphyrin having lower than D 4h symmetry.
- Preferred solubilizing polyoxyhydrocarbyl moieties include water soluble carbohydrates such as glucose, sucrose, maltotriose and the like; water soluble carbo ⁇ hydrate derivatives such as gluconic acid and mannitol, and oligosaccharides; polypeptides such as polysine and naturally occurring proteins; and water soluble polymers such as polyvinylpyrrolidone, poly(vinyl alcohol) , poly
- polyether such as polyoxyalkylenes including poly (ethylene glycol) , or other water soluble mixed oxyalky- lene polymers, and the like.
- a particularly preferred class of solubilizing poly ⁇ oxyhydrocarbyl moieties comprises poly(ethylene glycol) (PEG) and poly(ethylene glycol) derivatives, such as poly(ethylene glycol) monomethyl ether.
- PEG derivatives include PEG-silicon derived ethers.
- Many of these polymers are commercially available in a variety of molecular weights. Others may be conveniently prepared from commercially available materials, such as by coupling of an amino-PEG to a haloalkyl silyl or silane moiety.
- these polyoxyhydro ⁇ carbyl moieties When linked to a fluorophore moiety, these polyoxyhydro ⁇ carbyl moieties impart particularly advantageous qualities of solubility in aqueous solution with improved measured fluorescence decay time, and improved fluorescence inten ⁇ sity.
- the resulting marker components are water soluble and show decreased non-specific binding, especi ⁇ ally decreased binding tc serum albumin which has here ⁇ tofore been a problem with certain fluorophores, parti- cularly porphyrin or phthalocyanine dyes which have been functionalized with groups such as sulfonate to impart increased water solubility to the molecule.
- Non-specific binding of fluorophore or marker component impairs the accuracy of the resulting immunoassay.
- These marker components which comprise fluorophore linked to PEG may also exhibit improved fluorescence intensity in aqueous solution with decreased quenching.
- Suitable PEGs may vary in molecular weight from about 200 to about 20,000 or more. Choice of a particular mole- cular weight may depend on the particular fluorophore chosen and its molecular weight and degree of hydropho- bicity, as well as the particular application for which the fluorophore-PEG complex is to be used.
- marker components which comprise a central atom (for example, silicon) coupled to two PEG moieties may be characterized by measurements of transient state fluores ⁇ cence.
- the intensity of the two components polarized either parallel or perpendicular to the direction of polarization of the exciting pulse is monitored over a time period equal to about 3 times the decay time of the marker component.
- Such curves reflect extinction coefficient, quantum yield, decay time and state of polarization and supply sensitive indications on the chemical and physical condition of the marker component. For example, if the excited state is being deacti ⁇ vated or converted to the triplet state the overall intensities are lowered and the decay times shortened. If the rotary brownian motion of the molecule is being altered by an increase in viscosity or by being bound to a large molecule, the ratio of the intensity of the paral ⁇ lel to the perpendicular component is increased.
- marker components according to the present invention show, within experimental error of about 5%, the same intensities, decay time and polarization in DMF (an organic solvent) as in SAP (saline azide phosphate, an aqueous neutral buffer) . To some extent these properties are shared by other marker component preparations.
- a distinctive and important property of the marker compo ⁇ nents of the present invention is a insensitivity to (and lack of binding to) the components in serum which is evi ⁇ denced by a lack of any measured effect of serum on the intensities, decay time or relative magnitudes of the polarized components of the fluorescence. This property is crucial for the marker components to be useful for applications such as assays using biological materials. D. Preparation of Preferred Marker Components
- the appropri ⁇ ate fluorophore moiety having hydroxy or halide groups as axial ligands is reacted with a reactive form of the solu ⁇ bilizing polyoxyhydrocarbyl moiety in a ligand exchange reaction according to the general reaction scheme:
- Mel denotes the macrocyclic ligand, CA the central atom, X the displaced ligand and SM the solubilizing moiety.
- This reaction may be carried out neat or, if desired, in solvent. Suitable solvents include quinoline, THF, DMF, imidazole and the like. Suitable reaction tem ⁇ peratures may vary, depending on the nature of the macro- cyclic starting material and the solubilizing group.
- the reaction is generally complete in about 2 minutes to about 24 hours.
- the reaction mixture can be conveniently heated under reflux or by means such as a sand bath. For con ⁇ venience, the reaction may be carried out at ambient pressure.
- these marker components When used as fluorescent labels in fluorescence immunoassays, these marker components may be linked to one member of a specific binding pair ("labelled binding part ⁇ ner") or an analog of such a member.
- the marker component may be directly attached or conjugated thereto or attached or conjugated via a linker arm.
- 1,2,4,5-Tetracyanobenzene (Pfaltz & Bauer, 0.5 g, 2.8 mMol) was suspended in methanol (10 ml) in a three-neck round-bottom flask fitted with a reflux condenser and a gas inlet tube. The mixture was stirred at 25°C without external cooling while ammonia gas was rapidly introduced. During the first two minutes of ammonia introduction the temperature of the reaction mixture rose to greater than 50°C and the suspended solid dissolved completely. Within 5 minutes a precipitate began to form. Stirring at 40- 50°C with slow introduction of ammonia was continued for 1 hour. The precipitated solid was collected by filtra ⁇ tion, washed with methanol, and dried. This product exhibited a very low solubility in methanol.
- dicyano- diiminoisoindoline 350 mg, 1.8 mMol
- diimino- isoindoline 1.0 g, 6.9 mMol
- quinoline Fluka, 20 ml
- the mixture was stirred at 25°C while silicon tetra- chloride (Aldrich, 2.0 ml, 18 mMol) was added dropwise over a period of 1 minute.
- the flask was then fitted with a reflux condenser (using teflon tape) and a calcium chloride drying tube and stirred for one minute at 25°C.
- reaction flask was lowered into a large oil bath maintained at 180-185°C and efficient mag ⁇ netic stirring was continued for 30 minutes. The oil bath was then removed and the contents of the flask were allowed to cool to room temperature.
- step (C) The crude dicyanophthalocyanine from step (C) (1 gram) was placed in a flask with a stir bar and 6 ml of concentrated sulfuric acid and stirred at 50°C overnight. The mixture was then carefully diluted with 4 ml water and heated to 100°C for an additional 20 hours. Cooling and dilution with water (20 ml) gave a blue precipitate which was collected by filtration and washed with water. The solid was then transferred to a flask along with a stir bar and 20 ml of a 1.0 M potassium carbonate solution and stirred and heated at reflux for one hour. The suspension was then slowly and carefully acidified with concentrated HCl and then filtered and the resulting solid was washed with water and acetone and dried in a desiccator. This material (0.7 g) was used without further purification in the next step.
- the crude dicarboxy silicon phthalocyanine dihydrox- ide from step (D) (85 mg) was placed in a vial along with a stir bar and imidazole (160 mg, 2.3 mMol) and 1 ml of dry DMF. The mixture was stirred for 5 minutes at 25°C andthen3-isocyanatopropyldimethylchlorosilane (Petrarch, 110 ⁇ l, 0.68 mMol) was added to the stirred mixture over a period of 0.5 minutes. The vial was capped in order to exclude moisture and stirring at 25°C was continued for 20-40 hours.
- step (E) (Compound III) (3 mg, 5 x 10 ⁇ 3 mMol) , which had been obtained in partially purified form by chromatography on silica gel, was dissolved in methanol
- the resulting deep blue solution was heated to reflux for one hour. Removal of methanol under aspirator pressure at 25°C left a viscous blue oil which was taken up in water (0.5 ml) and applied to a small (10 ml wet volume) DEAE Sepha- dex anion ion exchange column (Pharmacia, 3.5 meq/g, 40- 120 micron, basic form ⁇ 1M K 2 C0 3 ) . The water-soluble blue dye was retained quantitatively by the column. The column was washed with water (15 ml) and the blue dye was then eluted in greater than 70% yield with 10-20 ml of a 15% aqueous acetic acid solution.
- Fig. 1 is a typical HPLC chromatogram of this prepar ⁇ ation (compound IV) .
- the yields for a typical dye preparation range from 25-65% of this fraction.
- the Diatron Analog System is diagramed in Fig. 3.
- the tunable dye laser used was a PTI model PL2300 nitrogen laser with a dye laser module. By changing the laser dye and adjusting the dye laser grating, 600 picosecond pulses with peak power of near 40 KWatts could be generated at wavelengths from 340 to 900 nm.
- a beam splitter was used to send a portion of each pulse to a pulse detector which consists of a high speed
- Hamamatsu photo diode The resulting output of the photo- diode was fed into a pulse shaper which converted the resulting 800 picosecond (ps) pulse into a 100 nanosecond (ns) pulse. This 100 ns pulse was then used as a gate for the Hamamatsu microchannel plate PMT whose gain was changed by 10,000 within a 2 ns time period. The PMT stayed at the high gain until the 100 ns was over.
- the dye laser module, reaction cell and pulse detector was positioned and connected such that the PMT was gated to its high sensitivity state approximately 2 ns after the laser pulse passed through the reaction cell.
- a filter was positioned in front of the PMT to guard against high scatter signals when required.
- a lens was used to image the fluorescence onto the PMT microchannel plate.
- a rotatable polarizer was positioned in the output optical path to measure the time dependent polari ⁇ zation of the fluorescence.
- a computer was used to trigger the laser.
- the laser output was detected by the digitizer via a connection to the pulse detector (not shown) .
- a programmable sweep on the digitizer set up the time spread to be measured after the laser pulse from 10 ns to as high as several seconds. Typically, the system was operated such that 512 data points were generated over a 20 ns time period.
- the dye preparations were analyzed for their inter ⁇ action with serum protein.
- the dye preparations were adjusted to 5 x 10" 9 M/L in FPIA buffer.
- These dye prep- arations were added to the following solutions to a final dye concentration of 5 x 10" 11 M/L: FPIA buffer, 0.5% bovine gamma globulin, 5.0% bovine serum, 5.0% normal human serum, 5.0% pooled human serum and 5.0% whole blood lysate.
- FPIA buffer 0.5% bovine gamma globulin
- 5.0% bovine serum 5.0% normal human serum
- 5.0% pooled human serum 5.0% whole blood lysate.
- Fig. 5 Typically, when a dye binds to a protein non-specifically (as can be seen with the "C" fraction) , a significant increase in fluor ⁇ escence polarization occurs. This makes it impossible to distinguish the specific polarization due to antibody binding from the non-specific due to protein-dye inter- action.
- Example 2 Linkers In certain polarization assays, it is advantageous to use a spacer or linker. These linker or spacer arms are useful when different ligands are terminated by either a carboxyl or amino group. In addition, such compounds are important when the probe needs to be separated (stood off) from the molecule with the antibody binding epitope. This may be necessary to reduce the potential of non-radiated transfer of energy when antibody binds the specific epi ⁇ tope and/or to eliminate stearic hinderance. These linker/spacer arms are generally the same in both the ligand-probe and ligand-protein immunogen used to raise antibodies to the ligand, in order to create a specific binding pair. In polarization immunoassays, it is desir ⁇ able that the spacer create a relatively inflexible linker moiety.
- caged dicarboxy silicon phthalocyanine is a carboxy-terminated dye
- Various linkers spacer arms
- Such compounds include piperazine, ethylenediamine, hex- anediamine, 6-amino hexanoic acid, 5-aminobutanoic acid, 12-aminododecanoic acid, alanine and other amino acids.
- the following methodology for preparation of the phthalocyanine-12 amino dodecanoic acid compounds is an example of the general reaction for such linkers:
- HOBT 1-hydroxybenzotriazole
- the new abducts were purified on reverse phase C-18 columns by HPLC.
- 12-aminododecanoic acid was used as a linker
- a 10 nm shift to 690 nm occurred, which matches commercially available 690 nm laser diodes .
- the change increased the dynamic range of the assay from 0.03 to greater than 0.30 millipolarization in buffer when bound to an antibody molecule.
- the 10 nm shift increased the signal-to-background ratio by moving away from the excitation maximum of fluor- escing background molecules found in biological fluids .
- Fig. 6 The absorbance spectrum in methanol for the purified caged dicarboxy silicon phthalocyanine dye-linker is shown in Fig. 6. There is a 10 nm shift from 680 for the frac ⁇ tion "B" dye (Fig. 2) , to 690 nm for the dye-linker.
- transient state fluorescence polarization was measured on the Diatron Analog System described in Exam ⁇ ple I, in FPIA buffer and glycerol at 680 nm and in glycerol at 690 nm. These data are shown in Figs. 7 and 8.
- Digoxin is a glycosylated steroid which, when used in patients with congestive heart failure, increases cardiac output, decreases heart size, venous pressure and blood volume, and relieves edema.
- digoxin has a very narrow therapeutic range (serum levels of 0.5 to 2.5 ng/ml) and is generally toxic at concentrations greater than 2.1 ng/ml. Accordingly, there is a need for a digoxin assay which can accurately and precisely deter ⁇ mine digoxin concentrations at these levels.
- the digoxin probe was prepared as follows: .2 mg of 3-aminodigoxigenin was placed in a 3.0 ml reaction vial and dissolved with 100 ⁇ l DMF. In a separate vial, 1.0 mg of caged dicarboxy silicon phthalocyanine (Compound IV from Example 1(G)) was dissolved in 400 ml DMF and then transferred to the reaction vial along with 200 ⁇ l of wash DMF for a total of 600 ⁇ l,. 4.2 mg of 1-hydroxybenzotria- zole (HOBT) was added to the reaction vial, which was then dissolved and mixed well.
- HOBT 1-hydroxybenzotria- zole
- the digoxin-phthalocyanine probe was purified as fol ⁇ lows: a slurry of 5 gm C-18 was made in acetone and poured into a 1x15 cm glass column. The acetone was removed by the application of light pressure, and the column was equilibrated by the addition of 4 column vol ⁇ umes of 70% methanol/30% water. The reaction mixture containing digoxin-phthalocyanine probe was applied to the column and flushed with 70% methanol/30% water. The probe was eluted with 80% methanol/20% water, concentrated by vacuum and further purified by two subsequent passes on HPLC. After the second chromatograph on HPLC, the probe was brought to dryness in vacuo.
- Fig. 9 depicts a chromatograph of the HPLC method semi-prep C-18 column with a mobile phase and gradient elution of methanol/water.
- Fig. 10 depicts the structure of the digoxin-phthalocyanine probe.
- the probe was analyzed in a Perkin-Elmer spectro- photometer (Lambda 4 c) in two solvents, methanol and
- Figs. 11 and 12 are repre- sentative spectra. Fluorescence decay time was determined to be 4.7 ns using the Diatron Analog System described in Example 1 (Fig. 13) .
- R gas constant
- T temperature (in °K)
- n solution viscosity volume of molecules
- the fluorescein probe is only slightly detectable above background in 5% serum and completely non-detectable in 10% urine.
- the phthalocyanine digoxin probe is detectable at a very sig- nificant level above background in both the same serum and urine samples.
- Example 4 Competitive Serum Assay for Digoxin: Sequential Binding Procedure
- Digoxin reacts with serum albumin and other serum proteins at many reaction sites. Probes made with a fluorescent dye and digoxin will also react. "Nonspeci ⁇ fic” binding or serum protein interactions were minimized in this procedure by the action of the cyclodextrin, which has an affinity for digoxin which exceeds digoxin's affi ⁇ nity for constituents in serum. Thus the cyclodextrin interferes with the binding of digoxin with serum consti ⁇ tuents, but allows for binding of digoxin with digoxin antibody. Thus, the assay was designed to allow both the serum digoxin and the digoxin probe to react with the digoxin antibody.
- Transient state polarization was measured as described in Studholme, et al. , Patent Application entitled “Fluorometer Detection System, " Lyon & Lyon Docket No. 195/129.
- the transient state optical system was installed in the Diatron "FAST-60 Analyzer, " which contains a laser diode operating at 685 nm was pulsed at a 10 MHz rate. Typically, the laser "on” time was approx ⁇ imately 3 nanoseconds.
- Photons from the solution were detected using a photomultiplier tube (PMT) operating in a single photon counting mode. The photon event along with the relative time of the photon event as compared with the laser pulse time was determined. By storing the individual photon event times a histogram of frequency of photons as a function of time was generated.
- PMT photomultiplier tube
- the Diatron FAST-60 Analyzer includes a transient- state optical system installed in an automated fluores ⁇ cence reader designed to measure fluorescence from immuno ⁇ assay reactions.
- the reader contains the optical system, motor control for position reaction cuvettes in front of the optical system, thermal control to hold the system at 35°C and a computer link to control the reader, analyze and display results and print those results.
- the results were formatted into transient-state polarization units or, by using a calibration curve, the results were transformed into concentration units of the analyte being measured.
- Fig. 16 shows a comparison of digoxin calibration curves by a standard fluorescence polarization procedure (Abbott's TDx ® Fluorescence Polarization Analyzer) and the homogeneous sequential binding assay procedure described in this Example.
- Fig. 17 displays a correlation plot of 37 serum samples assayed by a commercial digoxin test system manufactured by Abbott Laboratories (TDx ® Digoxin II In Vitro Test, Product #9511-60) and assayed by the digoxin assay procedure described in this example. A correlation of 0.96 and a slope of 0.98 were determined. The slope and y-intercept indicate no systematic bias.
- the dilution jump procedure described in this Example allows the assay to be performed in the presence of high concentrations of serum, and was designed to reduce "non ⁇ specific" interactions which compete with the antibody for binding to the digoxin and digoxin probe. While not wish ⁇ ing to be bound by any particular theory, applicants believe that when sample, antibody and digoxin probe are incubated in a small reaction volume, the "nonspecific” interactions initially compete with the antibody for binding to digoxin and digoxin probe. When the solution is diluted, the "nonspecific" protein interactions tend to disappear rapidly and only the specific antibody reaction remains.
- the signal-to- background data is represented as a ratio (signal counts/ background count) .
- steady state assays can be configured with acceptable signal-to-background ratios using the caged dicarboxy silicon phthalocyanine digoxin probe which is measured at 680 nm. There was an approxi ⁇ mately 10-fold enhancement in this ratio when transient state techniques were used to time-discriminate against fast fluorescers within the background and scattering bands.
- concentration of fluorescent probe in the fluorescein steady assay system is 2.5 x 10 "10 M/L.
- the procedure is as follows: 50 ⁇ l of lysing/buffer (see Example 5 above) diluent was mixed with 2.0 ⁇ l serum calibrator or serum, plasma or whole blood sample and 5.0 ⁇ l of rabbit anti-digoxin antibody. This mixture was incubated for 5 minutes and 2.5 ⁇ l of digoxin probe was added and incubated an additional 15 minutes. After this incubation, 1.0 ml FPIA buffer was added as a dilution jump. The transient state polarization measurements were made on the Diatron FAST-60 Analyzer described in Exam ⁇ ple 4.
- Sample blanks were prepared for each sample or calibrator by performing the same steps, with the excep ⁇ tion that buffer was added in place of the probe. The sample blank was then measured and subtracted from the measurements for the entire reaction mixtures.
- Fig. 20 displays a calibration curve for commercial serum calibrators containing known concentration of digoxin, which were assayed using the high sensitivity procedure.
- Example 8 Preparation of Whole Blood Calibrators
- Whole blood was obtained from two donors by drawing blood into VacutainerTM (Bector Dickinson) tubes containing EDTA anticoagulant. The tubes were mixed thoroughly on a standard laboratory sample rotator. Based on the average specific gravity of blood being 1.056, a series of six 2 ml volumes of whole blood were weighed using standard gravimetric technique. These samples were then spiked using a USP grade digoxin (200 ng/ml) to final concen ⁇ trations of 0, 0.5, 1.0, 2.0, 3.0, and 5.0 ng/ml whole blood. The whole blood calibrators were stored at 4.0 - 8.0 °C and were used within two weeks.
- Ratio, Serum Versus Whole Blood Applicants determined the signal-to-background ratio of the whole blood preparations which were prepared as described in Example 8 and compared the whole blood (i.e. , blank) intensity to the probe intensity. The resulting values comparing the whole blood and serum signal-to- background ratios are shown in Table 4. These measure ⁇ ments were made at working digoxin probe concentration of 5 X 10 "11 M/L in the transient state system. It can be seen that the net probe intensities remained constant even when the background intensities fluctuated.
- the average signal-to-noise ratio is 2 to 1 at probe concentrations of 2.5 X 10 "10 M/L, as contrasted with those found by homoge ⁇ neous transient state fluorescence for serum and whole blood of 77.6:1 and 26.7:1, respectively.
- Example 10 Homogeneous Whole Blood Digoxin Assay Clinical Study Previous whole blood immunoassays have been limited by many factors. For example, separation steps are required in many assay systems, enzymes and other sub ⁇ stances released from red blood cells cause interference in the assays, and the instrumentation is incapable of measuring analytes or reaction products through whole blood hemolysates.
- Applicants have developed a homoge- neous whole blood assay system which offers the clinical laboratory and other testing facilities significant advan ⁇ tages over currently used methods, including decreased labor cost, and decreased sample manipulation. In addi ⁇ tion, with a homogeneous 5 to 10 minute assay, the pro- cedure can be brought much closer to the patient, for example, to the bedside, emergency care facilities clinics and satellite testing facilities.
- Digoxin is widely distributed in body tissues. Serum and plasma have been the accepted samples for the assay of digoxin using the current commercially available test kits. Studies have shown a relative constant relationship between heart muscle and serum digoxin levels, thus vali ⁇ dating the use of digoxin serum levels in monitoring patients receiving the drug (Doherty, J.E., et. al.. 1978, "Clinical Pharmacokinetics of Digitalis Glycosides.” Pro ⁇ gress in Cardiovascular Diseases, Vol. XXI, No. 2 (Sept./ Oct.) ) .
- Each sample pair was ana ⁇ lyzed for serum digoxin levels determined by the Abbott TDx ® , Dade Stratus ® and Diatron FAST-60 Systems. Plasma levels were analyzed by Abbott TDx ® and Diatron FAST-60 Systems. Whole blood levels were analyzed by Abbott TDx ® and Diatron FAST-60 Systems.
- the Abbott TDx ® System used the TDx ® Digoxin II In Vitro Test, Product #9511-60 (Abbott Laboratories) .
- the Dade Stratus System used the Dade Stratus ® Digoxin Fluorometric Enzyme Immunoassay (Dade Diagnostics Division of Baxter Healthcare Division, Miami, Florida) .
- the Diatron FAST-60 System used the methods described in Example 5 and the apparatus described in Example 4 and Studholme, e al. , Lyon & Lyon Docket No. 195/129.
- the primary concern was whether the whole blood digoxin values were similar to the serum values.
- the whole blood lysates were clarified by centrifugation before assay.
- the study subjects were randomly selected patients currently on active digoxin therapy.
- the Diatron FAST-60 Digoxin Assay System consisted of (1) caged dicarboxy silicon phthalocyanine digoxin probe in FPIA buffer with 1% bovine gamma globulin; (2) rabbit anti-digoxin in FPIA buffer with 0.1% bovine gamma globu ⁇ lin; (3) lysing/buffer diluent; and (4) FPIA buffer (100 mM phosphate buffer with 1% sodium azide and .01% bovine gamma globulin) . Assay procedures were performed as follows:
- Diatron FAST-60 See Fig. 21.
- A. Abbott TDx ® Digoxin II In Vitro Test Performed according to manufacturer's instructions, except for the precipitation step. Digoxin extraction from whole blood was accomplished as follows: to 360 ⁇ l whole blood, an equal volume of Abbott -Precipitation Reagent (Digoxin II) was added with immediate vortexing for 30 sec ⁇ onds. The conical tubes were centrifuged at 10,000 RPMs for two minutes. The slightly brownish supernate was removed very carefully with a Pasteur pipette and transferred to the sample cup, to avoid the transfer of small particles.
- Abbott TDx ® Digoxin II In Vitro Test Performed according to manufacturer's instructions, except for the precipitation step. Digoxin extraction from whole blood was accomplished as follows: to 360 ⁇ l whole blood, an equal volume of Abbott -Precipitation Reagent (Digoxin II) was added with immediate vortexing for 30 sec ⁇ onds. The conical tubes were centrifuged at 10,000 RPMs for two minutes. The slightly brown
- Red blood cells were lysed prior to assay by addition of lysing buffer (0.001 M/L Tris buffer, pH 8.0 containing 5 x 10 ⁇ 5 M/L stearyl-lysolecithin) . Palmitoyl-lysolecithin and myristoyl-lysolecithin in Tris buffer are equally effective. These reagents are preferred in that they do not interfere with the immunoassay at this concentration, and that red cell ghost particle size is reduced in 30 to 60 seconds, thus reducing any effect of light scatter dur- ing the fluorescence measurements resulting in a homoge ⁇ neous, non-separation whole blood assay.
- lysing buffer 0.001 M/L Tris buffer, pH 8.0 containing 5 x 10 ⁇ 5 M/L stearyl-lysolecithin. Palmitoyl-lysolecithin and myristoyl-lysolecithin in Tris buffer are equally effective. These reagents are preferred in that they do not interfere with the
- the results of the testing are tabulated in Table 5.
- the values from the TDx ® and Stratus ® are the result of single point testing. Because the FAST-60 procedure used "manual pipetting" and automated instrumental analysis, the samples were run in duplicate and the raw values averaged.
- Figs. 22 through 26 The correlation data are found in Figs. 22 through 26. These include TDx ® serum versus FAST-60 whole blood (Fig. 22) , Stratus ® serum versus FAST-60 whole blood (Fig. 23) FAST-60 serum versus FAST-60 whole blood (Fig. 24) , TDx ® serum versus FAST-60 serum (Fig. 25) and Stratus ® serum versus FAST-60 serum (Fig. 26) .
- small analytes such as amikacin, gentamicin, netilmicin, tobra- mycin, carbamazepine, ethosuximide, valproic acid, diso- pyramide, lidocaine, procainamide, quinidine, methotrex- ate, amitriptyline, mortripyline, imipramine, desipramine, vancomycin and cyclosporine are particularly suited for the assays described herein due to their size.
- probes were prepared for digitoxin, theophylline, phenobarbital, thyroxine, N-acetylprocainamide, primidone and phenytoin.
- caged dicarboxy silicon phthalocyanine probes can be prepared for peptides.
- such probes were prepared for rubella virus peptide.
- the digitoxin probe was prepared as follows: 0.8 mg of 3-aminodigitoxigenin was placed in a 3.0 ml reaction vial and dissolved in 100 ⁇ l DMF. Caged dicarboxy silicon phthalocyanine (1.0 mg) was added to the reaction vial. Also added to the reaction vial were 0.5 mg HOBT and 2.0 mg EDAC and the resulting mixture was thoroughly mixed. The reaction mixture was stored overnight at about 4 to 8°C.
- the digitoxin probe was purified by procedures similar to those described in Example 3 for the digoxin probe.
- the structure of the caged dicarboxy silicon phthalocyanine-digitoxin probe is shown in Fig. 27.
- the theophylline probe was prepared as follows: 1.2 mg theophylline-8- (N-2-aminoethyl)butyramide was placed in a 3.0 ml reaction vial and dissolved in 100 ⁇ l DMF. In a separate vial, caged dicarboxy silicon phthalo ⁇ cyanine (1.0 mg) was dissolved in 400 ⁇ l DMF and then transferred to the reaction vial along with 200 ⁇ l of wash DMF (for a total of 600 ⁇ l DMF) . To the reaction vial was added 6.1 mg of HOBT, dissolved and mixed well. To make the final reaction mixture, 7.0 mg EDAC was added and the resulting mixture mixed thoroughly. The reaction mixture was stored overnight at about 4 to 8°C.
- the theophylline probe was purified using procedures similar to those described in Example 3 for the digoxin probe.
- the structure of the caged dicarboxy silicon phthalocyanine-digoxigenin probe is shown in Fig. 28.
- Phenobarbital 663 mg, was dissolved in 2.7 ml con- centrated sulfuric acid cooled in ice. With stirring, a cold solution of 0.16 ml concentrated nitric acid in 0.65 ml concentrated sulfuric acid was added dropwise over a period of 4 minutes. After 1/2 hour in the cold, the reaction mixture was poured into ice water. The precipi- tate was collected, washed with water, and dried in vacuo affording 0.03 g white solid.
- the phenobarbital probe was prepared as follows: 1.2 mg of 5-ethyl-5- (aminophenyl)barbituric acid (P-amino- phenobarbital) was placed in a 3.0 ml reaction vial and dissolved with 200 ⁇ l DMF. In a separate vial the caged dicarboxy silicon phthalocyanine (1.0 mg) was dissolved in 200 ⁇ l DMF and then transferred to the reaction vial. To the reaction vial was added 2.4 mg HOBT, dissolved and mixed well. To make the final reaction mixture, 2.8 mg of EDAC was added and mixed thoroughly. The reaction mixture was stored overnight at about 4 to 8°C.
- the phenobarbital probe was purified using procedures similar to those described in Example 3 for the digoxin probe.
- the structure of the caged dicarboxy silicon phthalocyanine probe is shown in Fig. 29.
- the thyroxine probe was prepared as follows: 1.0 mg of tetraiodothyroacetic acid-ethylenediamine (Tetrac-EDA) was placed in a 3.0 ml reaction vial and dissolved in 100 ⁇ l DMF. In a separate vial, caged dicarboxy silicon phthalocyanine (1.0 mg) was dissolved in 400 ⁇ l DMF and then transferred to the reaction vial along with 200 ⁇ l of wash DMF for a total of 600 ⁇ l. To the reaction vial was added 1.8 mg HOBT, dissolved and mixed well. To the final reaction mixture, 1.5 mg EDAC was added and the resulting mixture mixed thoroughly. The reaction mixture was stored overnight at about 4 to 8°C. C. Purification of Probe
- the thyroxine probe was purified using procedures similar to those described in Example 3 for the digoxin probe.
- the structure of the caged dicarboxy silicon phthalocyanine-thyroxine probe is shown Fig. 30.
- Example 15 Synthesis of Caged Dicarboxy Silicon Phthalocyanine-N-Acetylprocainamide A. Preparation of Desethyl-N-Acetylprocainamide Desethyl-N-acetylprocainamide was prepared by dis ⁇ solving 1.0 g of p-acetamidobenzoic acid and 0.7 g N-hydroxysuccinimide in 20 ml pyridine. To this solution was added 1.4 g of N, N'-dicyclohexylcarbodiimide. The reaction mixture was placed at 4°C for 18 hours, at which time the crystals were removed by filtration.
- the filtra ⁇ tion was brought to room temperature and with stirring, 0.51 g N-ethylethylenediamine was added. Stirring con ⁇ tinued for 3 hours, the solution was cooled to 4°C and allowed to react for an addition 24 hours at 4°C.
- the second crop of crystals was removed by filtration, dis ⁇ solved in 25 ml of distilled water.
- the pH was adjusted to 10 with sodium hydroxide to form a white precipitate of desethyl-N-acetylprocainamide .
- the resultant precipitate was dried in vacuo and stored at -20°C in a desiccator.
- the N-Acetylprocainamide probe was prepared as fol ⁇ lows: 1.0 mg desethyl- ⁇ -Acetylprocainamide was placed in a 3.0 ml reaction vial and dissolved with 100 ⁇ l DMF. In a separate vial, caged dicarboxy silicon phthalocyanine (1.0 mg) was dissolved in 400 ⁇ l DMF and then transferred to the reaction vial along with 200 ⁇ l of wash DMF for a total of 600 ⁇ l. To the reaction vial was added 4.2 mg HOBT, dissolved and mixed well. To make the final reac ⁇ tion mixture, 10.5 mg EDAC was added and mixed thoroughly. The reaction mixture was stirred overnight at about 4 to 8°C.
- the N-Acetylprocainamide probe was purified using procedures similar to those described in Example 4 for the digoxin probe.
- the structure of the caged dicarboxy sili ⁇ con phthalocyanine-N-acetylprocainamide probe is shown in Fig. 31.
- the primidone probe was prepared as follows: 0.8 mg 5-ethyl-5- (4-aminophenyl) hexahydropyrimidine-4, 6-dione (p-aminoprimidone) was placed in 100 ⁇ l DMF in a 3.0 ⁇ l reaction vial. To the reaction vial was added 1.0 mg caged dicarboxy silicon phthalocyanine (1.0 mg) and 3.1 mg HOBT. To make the final reaction mixture, 3.9 mg EDAC was added along with 150 ml DMF and the resulting mixture mixed thoroughly. The reaction mixture was stored over- night at about 4-8°C.
- the primidone probe was purified using procedures similar to those described in- Example 3 for the digoxin probe.
- the structure of the caged dicarboxy silicon phthalocyanine-primidone probe is shown in Fig. 37.
- Example 17 Synthesis of Caged Dicarboxy Silicon Phthalocyanine-Phenvtoin A. Preparation of Probe
- the phenytoin probe was prepared as follows: 1.2 mg of diphenylglycine was placed in a 3.0 ml reaction vial and dissolved with 100 ⁇ l DMF. In a separate vial, dicar- boxyphthalocyanine (3.0 mg) was dissolved in 400 ml DMF and then transferred to the reaction vial along with 200 ⁇ l of wash DMF for a total of 600 ⁇ l. To the reaction vial was added 6.1 mg of HOBT, dissolved and mixed well. To make the final reaction mixture, 7.0 mg of EDAC was added and mixed thoroughly. The reaction was stored at 4.0-8.0°C overnight.
- the phenytoin-phthalocyanine probe was purified using procedures similar to those described in Example 3 for the digoxin probe.
- the structure of the caged dicarboxy sili ⁇ con phthalocyanine-phenytoin probe is shown in Fig. 33.
- Caged dicarboxy silicon phthalocyanine dye (12 ⁇ moles) prepared according to Example 1 and purified by DEAE Sephadex chromatography was mixed with 1 ml of pyridine-pyridinium chloride buffer made by mixing 5 ml 1 M HCl with 0.5 ml pyridine. The solution was taken to dryness in a sublimation apparatus and the excess pyridine and pyridinium chloride was removed, thus assuring that all acetate ion present would be removed. The dry resi ⁇ dual dye was dissolved in anhydrous dichloromethane to make a 3.5 mM solution.
- the carboxylic acid groups of the dye were converted to the imidazolide by mixing 1 ml of 3.5 mM dye with 760 ⁇ l of 0.46 M carbonyl diimidazole and allowing 1.5 hour at room temperature for reaction, after which the solvent was removed .in vacuo.
- DMF was scavenged free of water and reactive amines by adding carbonyl diimidazole to a final concentration of 0.1 M.
- a portion of the reac ⁇ tion mixture was equilibrated with 10 mM phosphate, pH 7.6 by two treatments in a Minicon concentrator (Amicon Cor ⁇ poration, Danvers, MA, USA) and passed through a hydroxy- lapatite column (Bio Rad Laboratories, Richmond, CA, USA) equilibrated with 10 mM phosphate, pH 7.6. Free dye eluted at this stage and the labeled antibody was recov- ered by elution with 100 mM phosphate, pH 7.6.
- speci- ficity is defined as the proportion of individuals with negative test results for the disease that the test is intended to reveal, i.e.. true negative results as a proportion of the total number of true negative and false positive results.
- this assay demonstrated 100% specificity.
- sensitivity of a procedure can be defined as that pro ⁇ portion of individuals with a positive test result for the disease that the test intended to reveal , i.e. , true posi ⁇ tive results as a proportion of the total true positive and false negative results.
- Probe A synthetic rubella peptide for example, a portion of the E-. protein of the rubella virus (Therien strain) , can be synthesized by standard peptide synthesis proce ⁇ dure.
- the coupling of caged dicarboxy silicon phthalo ⁇ cyanine (prepared according to Example 1) to the synthetic rubella peptide was a four step process:
- Example 20 Immunological Evaluation of Phthalocyanine-Rubella Probe Two assay procedures were performed in order to evaluate the phthalocyanine-Rubella probe.
- the phthalo ⁇ cyanine-Rubella Probe was diluted in a 0.01 Tris buffer pH 8.0 containing 0.1 % bovine serum and 0.025% Tween 20.
- the probe concentration was determined to be 1.1 x 10" 11 M/L.
- Rubella peptide calibrators were made by diluting in the Tris buffer to the following concentrations: 0.0, 1.0 x 10' 12 , 2.7 x 10 "12 , and 5.4 x 10 "12 , 2.7 x 10 -11 , and 5.4 x 10 "11 .
- the antibody was made by hyper-immunizing a rabbit with the Rubella peptide. Dilutions were made in the Tris buffer described above.
- Tris buffer 25 ⁇ l Tris buffer, 20 ⁇ l antibody solution and 10 ⁇ l antibody solution and 10 ⁇ l of each peptide calibrator. The tubes were incubated at 35°C for 10 minutes. At this time, 15 ⁇ l of probe was added to each tube and incubated an additional 20 minutes at 35°C. After incubation 1.0 ml of Tris buffer was added and transient state polarization measurements were made.
- the typical inhibition curve is shown in Fig 35.
- probes can be made for peptide hormones such as luteiniz- ing hormone, follicular stimulating hormone, human chorio- gonadotropin, thyroid stimulating hormone.
- Angiotensin I Angiotensin II
- prolactin prolactin
- Probes can be made for peptides such as tumor markers (for example, carcino- embryonic antigen) as well.
- tumor markers for example, carcino- embryonic antigen
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85617692A | 1992-03-23 | 1992-03-23 | |
US856176 | 1992-03-23 | ||
PCT/US1993/002470 WO1993019366A1 (fr) | 1992-03-23 | 1993-03-23 | Immuno-essais par fluorescence au moyen de matrices fluorescentes exemptes d'agregat et de liant de serum |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0632893A1 true EP0632893A1 (fr) | 1995-01-11 |
EP0632893A4 EP0632893A4 (fr) | 1997-01-02 |
Family
ID=25323005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93908390A Ceased EP0632893A4 (fr) | 1992-03-23 | 1993-03-23 | Immuno-essais par fluorescence au moyen de matrices fluorescentes exemptes d'agregat et de liant de serum. |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0632893A4 (fr) |
CA (1) | CA2132708C (fr) |
WO (1) | WO1993019366A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6060598A (en) * | 1990-05-15 | 2000-05-09 | Hyperion, Inc. | Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding |
US5919922A (en) * | 1990-05-15 | 1999-07-06 | Hyperion, Inc. | Fluorescent dyes free of aggregation and serum binding |
US5880287A (en) * | 1990-05-15 | 1999-03-09 | Hyperion, Inc. | Polyoxyhydrocarbyl related products and methods for fluorescence assays |
US5824799A (en) * | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
US7322927B2 (en) | 1993-09-24 | 2008-01-29 | Biosite, Inc. | Hybrid phthalocyanine derivatives and their uses |
US6238931B1 (en) | 1993-09-24 | 2001-05-29 | Biosite Diagnostics, Inc. | Fluorescence energy transfer in particles |
US7083984B2 (en) | 1993-09-24 | 2006-08-01 | Biosite, Inc. | Hybrid phthalocyanine derivatives and their uses |
CA2215727C (fr) * | 1995-03-23 | 2003-12-30 | Kenneth F. Buechler | Derives hybrides de phthalocyanine et leurs utilisations |
US5876935A (en) * | 1997-01-08 | 1999-03-02 | Dade Behring Inc. | Luminescent specific binding assay |
EP1133531A1 (fr) * | 1998-11-25 | 2001-09-19 | Hyperion, Inc. | Colorants fluorescents solubles dans l'eau sans agregation et sans liaison au serum, produits et procedes associes |
EP1780213A1 (fr) * | 2005-10-27 | 2007-05-02 | 3M Innovative Properties Company | Silicium-urée-azolides, leur préparation et leur utilisation dans la préparation d'isocyanates de silicone |
EP2343974A4 (fr) * | 2008-08-15 | 2015-07-15 | Univ Georgetown | Canaux sodiques, maladie, et dosages et compositions apparentées |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0502723A2 (fr) * | 1991-03-05 | 1992-09-09 | Hitachi Chemical Co., Ltd. | Tétraazaporphine soluble dans l'eau et fluorochrome pour marquer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0645681B2 (ja) * | 1986-02-05 | 1994-06-15 | 美浜 久春 | 修飾ヘム |
AU636562B2 (en) * | 1986-12-15 | 1993-05-06 | British Technology Group Usa, Inc. | Monomeric phthalocyanine reagents |
WO1991018006A1 (fr) * | 1990-05-15 | 1991-11-28 | Diatron Corporation | Porphyrine fluorescente et phthalocyanine fluorescente, polyethylene glycol, polyol et derives de saccharide utilises comme sondes fluorescentes |
ES2164043T3 (es) * | 1990-05-15 | 2002-02-16 | Hyperion Inc | Marcador detectablemente marcado, que comprende un grupo fluoroforo, una sonda fluorescente que comprende el marcador y aplicaciones de los mismos. |
-
1993
- 1993-03-23 CA CA002132708A patent/CA2132708C/fr not_active Expired - Fee Related
- 1993-03-23 EP EP93908390A patent/EP0632893A4/fr not_active Ceased
- 1993-03-23 WO PCT/US1993/002470 patent/WO1993019366A1/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0502723A2 (fr) * | 1991-03-05 | 1992-09-09 | Hitachi Chemical Co., Ltd. | Tétraazaporphine soluble dans l'eau et fluorochrome pour marquer |
Non-Patent Citations (1)
Title |
---|
See also references of WO9319366A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0632893A4 (fr) | 1997-01-02 |
WO1993019366A1 (fr) | 1993-09-30 |
CA2132708A1 (fr) | 1993-09-30 |
CA2132708C (fr) | 2005-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6060598A (en) | Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding | |
US5464741A (en) | Palladium (II) octaethylporphine alpha-isothiocyanate as a phosphorescent label for immunoassays | |
Hemmilä | Fluoroimmunoassays and immunofluorometric assays. | |
Mathis | Rare earth cryptates and homogeneous fluoroimmunoassays with human sera | |
AU636562B2 (en) | Monomeric phthalocyanine reagents | |
EP0580979B1 (fr) | Procédé de détection par induction d'électrochimiluminescence | |
US9720004B2 (en) | Immunoassays employing non-particulate chemiluminescent reagent | |
EP0174744B1 (fr) | Transfert d'énergie fluorescente au moyen de phycobiliprotéines | |
US5846703A (en) | Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding | |
CA1133392A (fr) | Essai de liaison specifique pour marquage par fluorescence a excitation chimique | |
EP1019722B1 (fr) | Fluorophores polymeres ameliores par des fractions creant un microenvironnement hydrophobe et a restriction conformationnelle | |
JPH06500852A (ja) | 螢光化合物からの発光信号増幅方法 | |
JPS6337347B2 (fr) | ||
WO2006001944A1 (fr) | Azaporphyrines substituees en tant que marqueurs de fluorescence | |
EP0632893A1 (fr) | Immuno-essais par fluorescence au moyen de matrices fluorescentes exemptes d'agregat et de liant de serum | |
Boyer et al. | Evaluation of near infrared dyes as labels for immunoassays utilizing laser diode detection: Development of near infrared dye immunoassay (NIRDIA) | |
KR101846075B1 (ko) | 선형 업컨버전 형광 특성을 이용한 생체물질 검출 방법 | |
CN111675674A (zh) | 一种aie分子及其合成方法 | |
JPH03502333A (ja) | 蛍光イムノアッセイ、及びそれに使用する蛍光化合物とトレーサー | |
WO1990002334A1 (fr) | Reactifs et procedes de determination d'analytes | |
Sun et al. | Solid substrate phosphorescent immunoassay based on bioconjugated nanoparticles | |
JPS59101481A (ja) | 置換カルボキシフルオレセイン | |
US11982619B2 (en) | Method for detecting biomaterial using linear upconversion fluorescent property | |
JPH10332695A (ja) | 核酸,蛋白質等の検出方法 | |
Li et al. | Fluorescence and immunodiagnostic methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19941007 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19961118 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19970214 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HYPERION, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20030209 |